{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T04:54:42Z","timestamp":1794804882765,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG070941"],"award-info":[{"award-number":["R01AG070941"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG070941"],"award-info":[{"award-number":["R01AG070941"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG070941"],"award-info":[{"award-number":["R01AG070941"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG067505"],"award-info":[{"award-number":["R01AG067505"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["RF1R01AG053550"],"award-info":[{"award-number":["RF1R01AG053550"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG070941"],"award-info":[{"award-number":["R01AG070941"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["P30AG066444"],"award-info":[{"award-number":["P30AG066444"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["P01AG003991"],"award-info":[{"award-number":["P01AG003991"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["P01AG026276"],"award-info":[{"award-number":["P01AG026276"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011957","name":"Takeda Pharmaceutical Company Limited | Takeda Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006484","name":"AbbVie Inc. | AbbVie Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Predicting not just if, but also when, cognitively unimpaired individuals are likely to develop onset of Alzheimer\u02bcs disease (AD) symptoms would be useful to clinical trials and, eventually, clinical practice. Although clock models based on amyloid and tau positron emission tomography have shown promise in predicting the onset of AD symptoms, a model based on plasma biomarkers would be more accessible. Using longitudinal plasma %p-tau217 (the ratio of phosphorylated to non-phosphorylated tau at position 217) from two independent cohorts (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009258 and\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009345), clock models were used to estimate the age at plasma %p-tau217 positivity. The estimated age at plasma %p-tau217 positivity was associated with the age at onset of AD symptoms (adjusted\n                    <jats:italic>R<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    of 0.337\u22120.612) with a median absolute error of 3.0\u22123.7\u2009years. Notably, the time from %p-tau217 positivity to onset of AD symptoms was markedly shorter in older individuals. Similar models were constructed with data from one p-tau217\/A\u03b242 immunoassay and four plasma p-tau217 immunoassays. These findings suggest that the time until onset of AD symptoms can be estimated using a single blood test within a margin of error that is acceptable for use in clinical trials.\n                  <\/jats:p>","DOI":"10.1038\/s41591-026-04206-y","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T10:02:51Z","timestamp":1771495371000},"page":"1085-1094","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Predicting onset of symptomatic Alzheimer\u02bcs disease with plasma p-tau217 clocks"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3195-3456","authenticated-orcid":false,"given":"Kellen K.","family":"Petersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mil\u00e0-Alom\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1340-6694","authenticated-orcid":false,"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1662-0883","authenticated-orcid":false,"given":"Lianlian","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8644-7724","authenticated-orcid":false,"given":"Duygu","family":"Tosun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Saef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad S.","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Du-Cuny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janaky","family":"Coomaraswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Mordashova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie E.","family":"Rubel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0886-6218","authenticated-orcid":false,"given":"Emily A.","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie M.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2192-1699","authenticated-orcid":false,"given":"Jeffrey L.","family":"Dage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Ferber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gallen","family":"Triana-Baltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Baratta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin G.","family":"Rosenbaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0276-2899","authenticated-orcid":false,"given":"Carlos","family":"Cruchaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6764-3866","authenticated-orcid":false,"given":"Eric","family":"McDade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3400-0856","authenticated-orcid":false,"given":"David M.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Martin","family":"Sabandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7729-1702","authenticated-orcid":false,"given":"Randall J.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony W.","family":"Bannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Z.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1680-1465","authenticated-orcid":false,"given":"Suzanne E.","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma A\u03b2 and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer\u2019s Disease Project Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"4206_CR1","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack Jr, C. R. et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 20, 5143\u20135169 (2024).","journal-title":"Alzheimers Dement."},{"key":"4206_CR2","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0b013e3182840bbe","volume":"80","author":"CR Jack Jr","year":"2013","unstructured":"Jack Jr, C. R. et al. Brain \u03b2-amyloid load approaches a plateau. Neurology 80, 890\u2013896 (2013).","journal-title":"Neurology"},{"key":"4206_CR3","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N. Engl. J. Med. 367, 795\u2013804 (2012).","journal-title":"N. Engl. J. Med."},{"key":"4206_CR4","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/brain\/awz019","volume":"142","author":"BA Gordon","year":"2019","unstructured":"Gordon, B. A. et al. Tau PET in autosomal dominant Alzheimer\u2019s disease: relationship with cognition, dementia and other biomarkers. Brain 142, 1063\u20131076 (2019).","journal-title":"Brain"},{"key":"4206_CR5","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele, R. et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat. Med. 28, 2381\u20132387 (2022).","journal-title":"Nat. Med."},{"key":"4206_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4206_CR7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"4206_CR8","doi-asserted-by":"publisher","first-page":"111cm133","DOI":"10.1126\/scitranslmed.3002609","volume":"3","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A., Jack Jr, C. R. & Aisen, P. S. Testing the right target and right drug at the right stage. Sci. Transl. Med. 3, 111cm133 (2011).","journal-title":"Sci. Transl. Med."},{"key":"4206_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/547153a","volume":"547","author":"E McDade","year":"2017","unstructured":"McDade, E. & Bateman, R. J. Stop Alzheimer\u2019s before it starts. Nature 547, 153\u2013155 (2017).","journal-title":"Nature"},{"key":"4206_CR10","doi-asserted-by":"publisher","first-page":"e1823","DOI":"10.1212\/WNL.0000000000012775","volume":"97","author":"SE Schindler","year":"2021","unstructured":"Schindler, S. E. et al. Predicting symptom onset in sporadic Alzheimer disease with amyloid PET. Neurology 97, e1823\u2013e1834 (2021).","journal-title":"Neurology"},{"key":"4206_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ana.22248","volume":"69","author":"VL Villemagne","year":"2011","unstructured":"Villemagne, V. L. et al. Longitudinal assessment of A\u03b2 and cognition in aging and Alzheimer disease. Ann. Neurol. 69, 181\u2013192 (2011).","journal-title":"Ann. Neurol."},{"key":"4206_CR12","doi-asserted-by":"publisher","first-page":"e70551","DOI":"10.1002\/alz.70551","volume":"21","author":"MB Heston","year":"2025","unstructured":"Heston, M. B. et al. Factors associated with age at tau pathology onset and time from tau onset to dementia in Alzheimer's disease. Alzheimers Dement. 21, e70551 (2025).","journal-title":"Alzheimers Dement."},{"key":"4206_CR13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/ana.27285","volume":"98","author":"M Mila-Aloma","year":"2025","unstructured":"Mila-Aloma, M. et al. Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocks. Ann. Neurol. 98, 508\u2013523 (2025).","journal-title":"Ann. Neurol."},{"key":"4206_CR14","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1002\/sim.7300","volume":"36","author":"CA Budgeon","year":"2017","unstructured":"Budgeon, C. A. et al. Constructing longitudinal disease progression curves using sparse, short-term individual data with an application to Alzheimer\u2019s disease. Stat. Med. 36, 2720\u20132734 (2017).","journal-title":"Stat. Med."},{"key":"4206_CR15","volume":"12","author":"RL Koscik","year":"2020","unstructured":"Koscik, R. L. et al. Amyloid duration is associated with preclinical cognitive decline and tau PET. Alzheimers Dement. 12, e12007 (2020).","journal-title":"Alzheimers Dement."},{"key":"4206_CR16","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/ana.26891","volume":"95","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Timing of biomarker changes in sporadic Alzheimer\u2019s disease in estimated years from symptom onset. Ann. Neurol. 95, 951\u2013965 (2024).","journal-title":"Ann. Neurol."},{"key":"4206_CR17","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1093\/brain\/awac213","volume":"145","author":"TJ Betthauser","year":"2022","unstructured":"Betthauser, T. J. et al. Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. Brain 145, 4065\u20134079 (2022).","journal-title":"Brain"},{"key":"4206_CR18","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","volume":"19","author":"MS Rafii","year":"2023","unstructured":"Rafii, M. S. et al. The AHEAD 3-45 study: design of a prevention trial for Alzheimer\u2019s disease. Alzheimers Dement. 19, 1227\u20131233 (2023).","journal-title":"Alzheimers Dement."},{"key":"4206_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14338","volume":"21","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici, G. D. et al. Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimers Dement. 21, e14338 (2025).","journal-title":"Alzheimers Dement."},{"key":"4206_CR20","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1016\/j.neuron.2023.05.017","volume":"111","author":"H Hampel","year":"2023","unstructured":"Hampel, H. et al. Blood-based biomarkers for Alzheimer\u2019s disease: current state and future use in a transformed global healthcare landscape. Neuron 111, 2781\u20132799 (2023).","journal-title":"Neuron"},{"key":"4206_CR21","volume":"15","author":"JK Wisch","year":"2023","unstructured":"Wisch, J. K. et al. Predicting continuous amyloid PET values with CSF and plasma A\u03b242\/A\u03b240. Alzheimers Dement. 15, e12405 (2023).","journal-title":"Alzheimers Dement."},{"key":"4206_CR22","doi-asserted-by":"publisher","first-page":"5617","DOI":"10.1002\/alz.14073","volume":"20","author":"V Devanarayan","year":"2024","unstructured":"Devanarayan, V. et al. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease. Alzheimers Dement. 20, 5617\u20135628 (2024).","journal-title":"Alzheimers Dement."},{"key":"4206_CR23","doi-asserted-by":"publisher","first-page":"8074","DOI":"10.1002\/alz.14315","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler, S. E. et al. Head-to-head comparison of leading blood tests for Alzheimer\u2019s disease pathology. Alzheimers Dement. 20, 8074\u20138096 (2024).","journal-title":"Alzheimers Dement."},{"key":"4206_CR24","doi-asserted-by":"crossref","unstructured":"Barthelemy, N. R. et al. Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat. Med. 30, 1085\u20131095 (2024).","DOI":"10.1038\/s41591-024-02869-z"},{"key":"4206_CR25","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/brain\/awae346","volume":"148","author":"N Warmenhoven","year":"2025","unstructured":"Warmenhoven, N. et al. A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain 148, 416\u2013431 (2025).","journal-title":"Brain"},{"key":"4206_CR26","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jama.2024.13855","volume":"332","author":"S Palmqvist","year":"2024","unstructured":"Palmqvist, S. et al. Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA 332, 1245\u20131257 (2024).","journal-title":"JAMA"},{"key":"4206_CR27","doi-asserted-by":"crossref","unstructured":"Meyer, M. R. et al. Clinical validation of the PrecivityAD2 blood test: a mass spectrometry-based test with algorithm combining %p-tau217 and A\u03b242\/40 ratio to identify presence of brain amyloid. Alzheimers Dement. 20, 3179\u20133192 (2024).","DOI":"10.1002\/alz.13764"},{"key":"4206_CR28","doi-asserted-by":"crossref","unstructured":"Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain 146, 1592\u20131601 (2023).","DOI":"10.1093\/brain\/awac333"},{"key":"4206_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14411","volume":"21","author":"V Devanarayan","year":"2025","unstructured":"Devanarayan, V. et al. Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid-positive early Alzheimer\u2019s disease. Alzheimers Dement. 21, e14411 (2025).","journal-title":"Alzheimers Dement."},{"key":"4206_CR30","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist, S. et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat. Med. 27, 1034\u20131042 (2021).","journal-title":"Nat. Med."},{"key":"4206_CR31","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s43587-025-00835-z","volume":"5","author":"R Ossenkoppele","year":"2025","unstructured":"Ossenkoppele, R. et al. Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials. Nat. Aging 5, 883\u2013896 (2025).","journal-title":"Nat. Aging"},{"key":"4206_CR32","doi-asserted-by":"crossref","unstructured":"Rissman, R. A. et al. Plasma A\u03b242\/A\u03b240 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 20, 1214\u20131224 (2024).","DOI":"10.1002\/alz.13542"},{"key":"4206_CR33","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 263\u2013269 (2011).","journal-title":"Alzheimers Dement."},{"key":"4206_CR34","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 270\u2013279 (2011).","journal-title":"Alzheimers Dement."},{"key":"4206_CR35","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","volume":"81","author":"B Dubois","year":"2024","unstructured":"Dubois, B. et al. Alzheimer disease as a clinical-biological construct\u2014an international working group recommendation. JAMA Neurol. 81, 1304\u20131311 (2024).","journal-title":"JAMA Neurol."},{"key":"4206_CR36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1212\/WNL.0000000000000596","volume":"83","author":"DC Ryman","year":"2014","unstructured":"Ryman, D. C. et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 83, 253\u2013260 (2014).","journal-title":"Neurology"},{"key":"4206_CR37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","volume":"13","author":"RJ Bateman","year":"2017","unstructured":"Bateman, R. J. et al. The DIAN-TU Next Generation Alzheimer\u2019s prevention trial: adaptive design and disease progression model. Alzheimers Dement. 13, 8\u201319 (2017).","journal-title":"Alzheimers Dement."},{"key":"4206_CR38","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1038\/s41591-025-03617-7","volume":"31","author":"K Horie","year":"2025","unstructured":"Horie, K. et al. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer\u2019s disease. Nat. Med. 31, 2044\u20132053 (2025).","journal-title":"Nat. Med."},{"key":"4206_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaf158","volume":"7","author":"L Du","year":"2025","unstructured":"Du, L. et al. Onset ages of cerebrovascular disease and amyloid and effects on cognition in risk-enriched cohorts. Brain Commun. 7, fcaf158 (2025).","journal-title":"Brain Commun."},{"key":"4206_CR40","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3233\/JAD-215722","volume":"90","author":"SE Schindler","year":"2022","unstructured":"Schindler, S. E. Predicting symptom onset in sporadic Alzheimer\u2019s disease: \u2018How long do I have?\u2019 J. Alzheimers Dis. 90, 975\u2013979 (2022).","journal-title":"J. Alzheimers Dis."},{"key":"4206_CR41","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.jalz.2018.07.220","volume":"14","author":"LM Shaw","year":"2018","unstructured":"Shaw, L. M. et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer\u2019s disease. Alzheimers Dement. 14, 1505\u20131521 (2018).","journal-title":"Alzheimers Dement."},{"key":"4206_CR42","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson, O. et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 18, 2669\u20132686 (2022).","journal-title":"Alzheimers Dement."},{"key":"4206_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70535","volume":"21","author":"S Palmqvist","year":"2025","unstructured":"Palmqvist, S. et al. Alzheimer\u2019s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer\u2019s disease within specialized care settings. Alzheimers Dement. 21, e70535 (2025).","journal-title":"Alzheimers Dement."},{"key":"4206_CR44","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamaneurol.2025.1100","volume":"82","author":"A Pichet Binette","year":"2025","unstructured":"Pichet Binette, A. et al. Evaluation of the revised criteria for biological and clinical staging of Alzheimer disease. JAMA Neurol. 82, 666\u2013675 (2025).","journal-title":"JAMA Neurol."},{"key":"4206_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2024.100008","volume":"12","author":"G Farrar","year":"2025","unstructured":"Farrar, G., Weber, C. J. & Rabinovici, G. D. Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer\u2019s Association Research Roundtable. J. Prev. Alzheimers Dis. 12, 100008 (2025).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"4206_CR46","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jalz.2012.01.001","volume":"8","author":"MJ Figurski","year":"2012","unstructured":"Figurski, M. J. et al. Improved protocol for measurement of plasma \u03b2-amyloid in longitudinal evaluation of Alzheimer\u2019s Disease Neuroimaging Initiative study patients. Alzheimers Dement. 8, 250\u2013260 (2012).","journal-title":"Alzheimers Dement."},{"key":"4206_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14264","volume":"21","author":"LM Shaw","year":"2025","unstructured":"Shaw, L. M. et al. ADNI Biomarker Core: a review of progress since 2004 and future challenges. Alzheimers Dement. 21, e14264 (2025).","journal-title":"Alzheimers Dement."},{"key":"4206_CR48","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris, J. C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412\u20132414 (1993).","journal-title":"Neurology"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04206-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04206-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04206-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:02:36Z","timestamp":1774018956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04206-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4206"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04206-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7059258\/v1","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.K.P. has served as a consultant for Eli Lilly and Company. Y.L. is the co-inventor of the technology \u2018Novel Tau isoforms to predict onset of symptoms and dementia in Alzheimer\u2019s disease\u2019, which is in the process of licensing by C2N Diagnostics. Z.S.S. and G.T.-B. are employed by Johnson & Johnson Innovative Medicine and may receive salary and stock for their employment. L.D.-C. and Y.M. are employed by AbbVie Deutschland GmbH & Co. KG. J.C. and M.B. receive salary and company stock as compensation for their employment with Takeda Pharmaceutical Company. C.E.R. and K.F. are employees of and may own stock in Biogen. E.A.M. is employed by the Alzheimer\u2019s Association. L.M.S. receives funding from the NIA for ADNI4 and from the NIA for the University of Pennsylvania ADRC P30 for the Biomarker Core. J.L.D. is an inventor on patents or patent applications of Eli Lilly and Company relating to the assays, methods, reagents and\/or compositions of matter for P-tau assays and A\u03b2-targeting therapeutics. J.L.D. has served or is serving as a consultant or on advisory boards for Eisai, AbbVie, Genotix Biotechnologies Inc., Gates Ventures, Gate Neurosciences, Dolby Family Ventures, Karuna Therapeutics, AlzPath Inc., Cognito Therapeutics, Inc., Prevail Therapeutics, Neurogen Biomarking, Spear Bio, the University of Kentucky, Rush University, Tymora and Quanterix. J.L.D. has received research support from ADx Neurosciences, Fujirebio, Roche Diagnostics and Eli Lilly and Company in the past 2\u2009years. J.L.D. has received speaker fees from Eli Lilly and Company and LabCorp. J.L.D. is a founder of and advisor to Monument Biosciences. J.L.D. has stock or stock options in Eli Lilly and Company, Genotix Biotechnologies, AlzPath Inc., Neurogen Biomarking and Monument Biosciences. N.J.A. has received speaking fees from Eli Lilly, Biogen, Quanterix and Alamar Biosciences. H.Z. has served on scientific advisory boards and\/or as a consultant for AbbVie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave; has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Eli Lilly, Novo Nordisk, Roche and WebMD; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). C.C. has received research support from GlaxoSmithKline and Eisai. C.C. is a member of the scientific advisory board of Circular Genomics and owns stocks. C.C. is also a member of the scientific advisory board of Admit and has served on the scientific advisory boards of GlaxoSmithKline and Novo Nordisk. E.M.M. has participated in speaker engagements for Eisai, Neurology Live and Projects in Knowledge-Kaplan. E.M.M. has had advisory board roles, consulting and data safety monitoring board (DSMB) relationships with Eli Lilly, Alnylam, Alector, Alzamend, Sanofi, AstraZeneca, F. Hoffmann-La Roche, Grifols and Merck. D.M.H. and R.J.B. have equity ownership interest in C2N Diagnostics. D.M.H. and R.J.B. receive income from C2N Diagnostics for serving on the scientific advisory board. D.M.H. is on the scientific advisory board of Genentech, Denali, Cajal Neurosciences, Acta Pharmaceuticals and Switch and consults for Alnylam, Pfizer and Roche. R.J.B. is a co-inventor on the following US patent applications: \u2018Methods to detect novel tau species in CSF and use thereof to track tau neuropathology in Alzheimer\u2019s disease and other tauopathies\u2019 and \u2018CSF phosphorylated tau and amyloid beta profiles as biomarkers of Tauopathies\u2019. R.J.B. is a co-inventor on a non-provisional patent application: \u2018Methods of diagnosing and treating based on site-specific tau phosphorylation\u2019. R.J.B. is an unpaid scientific advisory board member of Roche and Biogen and receives research funding from Avid Radiopharmaceuticals, Janssen, Roche\/Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb and Novartis. A.W.B. receives salary and company stock as compensation for his employment with AbbVie. W.Z.P. was previously employed by the National Institute of Mental Health and is a stockholder in Merck & Co. W.Z.P. is a Co-Chair Emeritus for the FNIH Biomarkers Consortium Neuroscience Steering Committee. W.Z.P. serves as a consultant for Karuna, Neurocrine, Neumarker and Vaaji and receives grant support from the NIA along with stock options from Praxis Bioresearch. S.E.S. has served on scientific advisory boards on biomarker testing and education for Eisai and Novo Nordisk and has received speaking fees for presentations on biomarker testing from Eisai, Eli Lilly, Novo Nordisk, Medscape and PeerView. She has provided unpaid scientific advising to Eisai, Johnson & Johnson Innovative Medicine, Eli Lilly, Biogen, Acumen, Cognito Therapeutics and Danaher. M.M.-A., L.D.-C., C.X., D.T., B.S., E.G.R., J.C.M. and J.M.S. have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}